BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim S, Park J, Shim MK, Um W, Yoon HY, Ryu JH, Lim DK, Kim K. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics 2019;9:7906-23. [PMID: 31695807 DOI: 10.7150/thno.38425] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Banik N, Yang SB, Kang TB, Lim JH, Park J. Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules. Int J Mol Sci 2021;22:10524. [PMID: 34638867 DOI: 10.3390/ijms221910524] [Reference Citation Analysis]
2 Bonacina F, Da Dalt L, Catapano AL, Norata GD. Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. Mol Aspects Med 2021;77:100918. [PMID: 33032828 DOI: 10.1016/j.mam.2020.100918] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Lin L, Chen Y, Yan L, Liu Y, Ni J, Yang H, Li H. Analysis of clinical trials of new drugs in China as of 2019. Drug Discov Today 2020;25:2080-8. [PMID: 33017690 DOI: 10.1016/j.drudis.2020.09.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yu N, Ding M, Li J. Near-Infrared Photoactivatable Immunomodulatory Nanoparticles for Combinational Immunotherapy of Cancer. Front Chem 2021;9:701427. [PMID: 34109160 DOI: 10.3389/fchem.2021.701427] [Reference Citation Analysis]
5 Li L, Zou J, Dai Y, Fan W, Niu G, Yang Z, Chen X. Burst release of encapsulated annexin A5 in tumours boosts cytotoxic T-cell responses by blocking the phagocytosis of apoptotic cells. Nat Biomed Eng 2020;4:1102-16. [PMID: 32807941 DOI: 10.1038/s41551-020-0599-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
6 Kyu Shim M, Yang S, Sun IC, Kim K. Tumor-Activated Carrier-Free Prodrug Nanoparticles for Targeted Cancer Immunotherapy: Preclinical Evidence for Safe and Effective Drug Delivery. Adv Drug Deliv Rev 2022;:114177. [PMID: 35245568 DOI: 10.1016/j.addr.2022.114177] [Reference Citation Analysis]
7 Xiao Z, Zhang Q, Guo X, Villanova J, Hu Y, Külaots I, Garcia-Rojas D, Guo W, Colvin VL. Libraries of Uniform Magnetic Multicore Nanoparticles with Tunable Dimensions for Biomedical and Photonic Applications. ACS Appl Mater Interfaces 2020;12:41932-41. [PMID: 32812740 DOI: 10.1021/acsami.0c09778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Gupta B, Kim JO. Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. J Pharm Investig 2021;51:399-412. [DOI: 10.1007/s40005-021-00527-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Chen X, Yang J, Wang L, Liu B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 2020;10:6011-23. [PMID: 32483434 DOI: 10.7150/thno.38742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
10 Liu Y, Guo J, Huang L. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics 2020;10:3099-117. [PMID: 32194857 DOI: 10.7150/thno.42998] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
11 Pilch J, Kowalik P, Bujak P, Nowicka AM, Augustin E. Quantum Dots as a Good Carriers of Unsymmetrical Bisacridines for Modulating Cellular Uptake and the Biological Response in Lung and Colon Cancer Cells. Nanomaterials (Basel) 2021;11:462. [PMID: 33670297 DOI: 10.3390/nano11020462] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Egilmez NK. Cytokine-Encapsulated Biodegradable Microspheres for Immune Therapy. Immunological Investigations 2020;49:824-39. [DOI: 10.1080/08820139.2020.1752713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Wang Q, Liu J. Medulloblastoma: Immune microenvironment and targeted nano-therapy. OpenNano 2022;6:100035. [DOI: 10.1016/j.onano.2022.100035] [Reference Citation Analysis]
14 Chen X, Chen M. Critical reviews of immunotheranostics. Theranostics 2020;10:7403-5. [PMID: 32642000 DOI: 10.7150/thno.48966] [Reference Citation Analysis]
15 Um W, Gupta A, Song SH, Kim CH, Park JH. Biomaterials as Antigen Delivery Carrier for Cancer Immunotherapy. Macromol Res 2021;29:834-42. [DOI: 10.1007/s13233-021-9095-3] [Reference Citation Analysis]
16 Lan H, Zhang W, Jin K, Liu Y, Wang Z. Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective. Drug Deliv 2020;27:1248-62. [PMID: 32865029 DOI: 10.1080/10717544.2020.1809559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Yang S, Sun IC, Hwang HS, Shim MK, Yoon HY, Kim K. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy. J Mater Chem B 2021;9:3983-4001. [PMID: 33909000 DOI: 10.1039/d1tb00397f] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Uzair B, Liaqat A, Iqbal H, Menaa B, Razzaq A, Thiripuranathar G, Fatima Rana N, Menaa F. Green and Cost-Effective Synthesis of Metallic Nanoparticles by Algae: Safe Methods for Translational Medicine. Bioengineering (Basel) 2020;7:E129. [PMID: 33081248 DOI: 10.3390/bioengineering7040129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
19 Sreeharsha N, Chitrapriya N, Jang YJ, Kenchappa V. Evaluation of nanoparticle drug-delivery systems used in preclinical studies. Ther Deliv 2021;12:325-36. [PMID: 33759568 DOI: 10.4155/tde-2020-0116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Yang S, Shim MK, Kim WJ, Choi J, Nam GH, Kim J, Kim J, Moon Y, Kim HY, Park J, Park Y, Kim IS, Ryu JH, Kim K. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials 2021;272:120791. [PMID: 33831739 DOI: 10.1016/j.biomaterials.2021.120791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Cho H, Shim MK, Yang S, Song S, Moon Y, Kim J, Byun Y, Ahn CH, Kim K. Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy. Pharmaceutics 2021;14:83. [PMID: 35056979 DOI: 10.3390/pharmaceutics14010083] [Reference Citation Analysis]
22 Ghafari M, Haghiralsadat F, Khanamani Falahati-Pour S, Zavar Reza J. Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy. J Cell Biochem 2020;121:3584-92. [PMID: 31907989 DOI: 10.1002/jcb.29651] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
23 Sun M, Yao S, Fan L, Fang Z, Miao W, Hu Z, Wang Z. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy. Small 2021;:e2106296. [PMID: 34914185 DOI: 10.1002/smll.202106296] [Reference Citation Analysis]
24 Patil-Sen Y. Advances in nano-biomaterials and their applications in biomedicine. Emerg Top Life Sci 2021;5:169-76. [PMID: 33825835 DOI: 10.1042/ETLS20200333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Sunil V, Mozhi A, Zhan W, Teoh JH, Wang CH. Convection enhanced delivery of light responsive antigen capturing oxygen generators for chemo-phototherapy triggered adaptive immunity. Biomaterials 2021;275:120974. [PMID: 34166911 DOI: 10.1016/j.biomaterials.2021.120974] [Reference Citation Analysis]
26 Cai S, Chen Z, Wang Y, Wang M, Wu J, Tong Y, Chen L, Lu C, Yang H. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy. Theranostics 2021;11:1970-81. [PMID: 33408792 DOI: 10.7150/thno.45777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Andreana I, Repellin M, Carton F, Kryza D, Briançon S, Chazaud B, Mounier R, Arpicco S, Malatesta M, Stella B, Lollo G. Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies. Pharmaceutics 2021;13:278. [PMID: 33669654 DOI: 10.3390/pharmaceutics13020278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Wu G, Deng Z, Jin Z, Wang J, Xu B, Zeng J, Peng M, Wen Z, Guo Y. Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study. Biomed Res Int 2020;2020:1346045. [PMID: 32596278 DOI: 10.1155/2020/1346045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Cho T, Han HS, Jeong J, Park EM, Shim KS. A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19. Int J Mol Sci 2021;22:2815. [PMID: 33802169 DOI: 10.3390/ijms22062815] [Reference Citation Analysis]
30 Taefehshokr S, Parhizkar A, Hayati S, Mousapour M, Mahmoudpour A, Eleid L, Rahmanpour D, Fattahi S, Shabani H, Taefehshokr N. Cancer immunotherapy: Challenges and limitations. Pathol Res Pract 2021;229:153723. [PMID: 34952426 DOI: 10.1016/j.prp.2021.153723] [Reference Citation Analysis]
31 Yang Q, Shi G, Chen X, Lin Y, Cheng L, Jiang Q, Yan X, Jiang M, Li Y, Zhang H, Wang H, Wang Y, Wang Q, Zhang Y, Liu Y, Su X, Dai L, Tang M, Li J, Zhang L, Qian Z, Yu D, Deng H. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Theranostics 2020;10:8382-99. [PMID: 32724476 DOI: 10.7150/thno.45391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
32 Ju Y, Liao H, Richardson JJ, Guo J, Caruso F. Nanostructured particles assembled from natural building blocks for advanced therapies. Chem Soc Rev 2022. [PMID: 35471996 DOI: 10.1039/d1cs00343g] [Reference Citation Analysis]
33 Zhang Y, Yuan T, Li Z, Luo C, Wu Y, Zhang J, Zhang X, Fan W. Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment. ACS Biomater Sci Eng 2021;7:1515-25. [PMID: 33793187 DOI: 10.1021/acsbiomaterials.1c00081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zhang X, Zhang H, Gu J, Zhang J, Shi H, Qian H, Wang D, Xu W, Pan J, Santos HA. Engineered Extracellular Vesicles for Cancer Therapy. Adv Mater 2021;33:e2005709. [PMID: 33644908 DOI: 10.1002/adma.202005709] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
35 Qiao L, Yang H, Shao X, Yin Q, Fu X, Wei Q. Research Progress on Nanoplatforms and Nanotherapeutic Strategies in Treating Glioma. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.1c00856] [Reference Citation Analysis]
36 Li F, Liang Y, Wang M, Xu X, Zhao F, Wang X, Sun Y, Chen W. Multifunctional nanoplatforms as cascade-responsive drug-delivery carriers for effective synergistic chemo-photodynamic cancer treatment. J Nanobiotechnology 2021;19:140. [PMID: 34001157 DOI: 10.1186/s12951-021-00876-7] [Reference Citation Analysis]
37 Deng H, Zhou Z, Yang W, Lin LS, Wang S, Niu G, Song J, Chen X. Endoplasmic Reticulum Targeting to Amplify Immunogenic Cell Death for Cancer Immunotherapy. Nano Lett 2020;20:1928-33. [PMID: 32073871 DOI: 10.1021/acs.nanolett.9b05210] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 29.5] [Reference Citation Analysis]
38 Zhang Y, Guo C, Liu L, Xu J, Jiang H, Li D, Lan J, Li J, Yang J, Tu Q, Sun X, Alamgir M, Chen X, Shen G, Zhu J, Tao J. ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death. Theranostics 2020;10:11197-214. [PMID: 33042278 DOI: 10.7150/thno.44920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Du W, Yang X, He S, Wang J, Guo Y, Kou B, Jiang Y, Bian P, Li B, Yin L. Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer. Drug Deliv 2021;28:920-9. [PMID: 33974471 DOI: 10.1080/10717544.2021.1914777] [Reference Citation Analysis]
40 Zhu M, Yang M, Zhang J, Yin Y, Fan X, Zhang Y, Qin S, Zhang H, Yu F. Immunogenic Cell Death Induction by Ionizing Radiation. Front Immunol 2021;12:705361. [PMID: 34489957 DOI: 10.3389/fimmu.2021.705361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Chen J, Huang J. Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer. J Mater Res 2020;35:3296-303. [DOI: 10.1557/jmr.2020.321] [Reference Citation Analysis]